Expression And Significance Analyses Of SFRP-1in Prostate Cancer

Prostate cancer is one of the common urinary tract malignant tumor.The incidenceof prostate cancer is located in the second place of malignant tumor in older men. Inrecent years the incidence of prostate cancer is increasing in our country.Its incidencehas become the third place of the male urogenital system tumors.Prostate cancer hasmuch therapies, including radical surgery, radiotherapy and endocrine therapy. Theendocrine therapy is a classic treatment of prostate cancer.The state of illness of mostpatients can be improved through the endocrine therapy,but it will be deteriorated afteran average of18months of endocrine therapy.The majority of prostate cancers relapseto castrate resistant prostate cancer that clinical doctors are helpless to. Castrate resistantprostate cancer is with poor prognosis. radical surgery is the main treatment to prostatecancer. In China,the prostate cancer patients are in the middle-late period when they seedoctor,so the simply radical surgery is not well. Therefore,the radical surgery is oftencombined with endocrine therapy. But the biology of prostate cancer is verycomplicated. Some had no any effect on the survival of patients with tumor and don’tneed any special treatment;Others will be shift and threaten patient’s life.The patientsneed to be taken reasonable and effective treatment as soon as possible.Some is withoutany clinical symptoms and is found with prostate cancer in accidental condition;Otherssymptoms for starting is shift.Some statistics show half of the male population olderthan50years old can be found with prostate cancer cells,but most do not need to treat intheir all life.The tumor cells will not affect the survival time of the crowd. Such as excessive treatment for these patients, not only increase the burden of the patients, butalso affect the patient’s quality of life. Based on the above reasons, finding an effectivemarker that can estimate the prognosis of prostate cancer become a hot topic in thestudy of prostate cancer.WNT pathway was found for it is associated with embryonic development andnow is regard as that the abnormal activation of the pathway is closely related to thegrowth of tumor. It has been proved in many aspects. SFRP-1is named as the proteinregion of CRD have homology with Frizzled.SFRP-1curb WNT pathways to suppresstumor occurrence and development through the competitive inhibition of WNTcombined with Frizzled. Numerous studies have demonstrated the suppressing functionof SFRP-1.This experiment discuss whether SFRP-1protein can predict the prognosis ofprostate cancer and provide basis for individualized treatment in patients with prostatecancer through studying the correlation between SFRP-1protein expression in prostatecancer and prostate cancer related indicators、 endocrine treatment survival time byanalysis of61cases of prostate cancer specimens.Methods: immunohistochemical staining was used to detect61cases of prostatecancer tissue samples without any treatment to check up the expression of SFRP-1,analysis of the relationshipbetween the expression of protein SFRP-1and Gleasonscore、metastasis of prostate cancer、PSA、the effect of endocrine therapy and survivaltime.Results:1.SFRP-1positive expression rate is74.1%in the prostate cancer tissuesof Gleason score≤7. SFRP-1positive expression rate is47.1%in the prostate cancertissues of Gleason score＞7.They are with significant difference (P＜0.05).2. SFRP-1positive expression rate is54.3%in the prostate cancer tissues with metastasis. SFRP-1positive expression rate is65.4%in the prostate cancer tissues without metastasis.Theyare without significant difference (P＞0.05).3. SFRP-1positive expression rate is58.3%in the prostate cancer tissues of PSA≤20ng/ml. SFRP-1positive expression rateis59.2%in the prostate cancer tissues of PSA＞20ng/ml. They are without significant difference (P＞0.05).4. SFRP-1positive expression rate is73.9%in the prostate cancertissues of patients with endocrine therapy effective. SFRP-1positive expression rate is40.9%in the prostate cancer tissues of patients without endocrine therapyeffective.They are with significant difference (P＜0.05).5.The difference of survivaltime between negative expression group and positive expression group is significantthrough the Log Rank test analysis (P＜0.05).The survival time of positive expression islonger.Conclusion: SFRP-1expression in prostate cancer organizations is related to theGleason scores of prostate cancer、the survival time and the effect of endocrine therapy,but has nothing to do with the transfer of tumor and PSA. SFRP-1can be used for theassessment of the effect of endocrine therapy and provide the basis of individualizedtreatment for prostate cancer.